X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (52513) 52513
Newspaper Article (216) 216
Newsletter (199) 199
Magazine Article (49) 49
Book Chapter (45) 45
Trade Publication Article (20) 20
Book / eBook (17) 17
Conference Proceeding (4) 4
Dissertation (4) 4
Transcript (4) 4
Web Resource (4) 4
Streaming Video (2) 2
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (42143) 42143
oncology (27749) 27749
female (21435) 21435
lung neoplasms - drug therapy (19760) 19760
male (19390) 19390
carcinoma, non-small-cell lung - drug therapy (19199) 19199
cancer (17268) 17268
middle aged (16753) 16753
aged (15651) 15651
chemotherapy (14524) 14524
lung cancer (12278) 12278
lung neoplasms - pathology (11852) 11852
adult (11074) 11074
carcinoma, non-small-cell lung - pathology (10232) 10232
tumors (9088) 9088
metastasis (8541) 8541
animals (8489) 8489
cell line, tumor (8331) 8331
apoptosis (8224) 8224
prognosis (8173) 8173
antineoplastic combined chemotherapy protocols - therapeutic use (7919) 7919
carcinoma (7763) 7763
lung cancer, non-small cell (7710) 7710
care and treatment (7588) 7588
expression (7237) 7237
treatment outcome (7154) 7154
antineoplastic agents - therapeutic use (6904) 6904
research (6647) 6647
cancer therapies (6631) 6631
lung neoplasms - genetics (6470) 6470
carcinoma, non-small-cell lung - genetics (6138) 6138
survival (6082) 6082
mutation (5999) 5999
neoplasm staging (5995) 5995
aged, 80 and over (5864) 5864
analysis (5458) 5458
proteins (5340) 5340
gene expression (5291) 5291
non-small cell lung cancer (5227) 5227
mice (5174) 5174
cisplatin (4834) 4834
health aspects (4777) 4777
kinases (4721) 4721
medical prognosis (4675) 4675
lung neoplasms - mortality (4667) 4667
genetic aspects (4462) 4462
patients (4417) 4417
lung neoplasms - metabolism (4404) 4404
non-small cell lung carcinoma (4317) 4317
carcinoma, non-small-cell lung - mortality (4271) 4271
therapy (4196) 4196
antineoplastic agents - pharmacology (4171) 4171
respiratory system (4163) 4163
cell biology (4152) 4152
pharmacology & pharmacy (4002) 4002
carcinoma, non-small-cell lung - metabolism (3833) 3833
development and progression (3830) 3830
survival analysis (3816) 3816
gefitinib (3680) 3680
medicine & public health (3669) 3669
medicine (3555) 3555
survival rate (3550) 3550
breast-cancer (3539) 3539
immunohistochemistry (3476) 3476
metastases (3370) 3370
studies (3362) 3362
cisplatin - administration & dosage (3341) 3341
signal transduction (3334) 3334
cell lung-cancer (3332) 3332
research article (3296) 3296
disease-free survival (3264) 3264
retrospective studies (3256) 3256
adenocarcinoma (3180) 3180
lung-cancer (3165) 3165
hematology, oncology and palliative medicine (3141) 3141
cell proliferation (3139) 3139
radiotherapy (3104) 3104
surgery (3095) 3095
apoptosis - drug effects (3072) 3072
drug therapy (3044) 3044
gene expression regulation, neoplastic (3043) 3043
immunotherapy (3013) 3013
biomarkers (3009) 3009
cell cycle (2973) 2973
clinical trials (2950) 2950
squamous cell carcinoma (2945) 2945
biochemistry & molecular biology (2931) 2931
breast cancer (2868) 2868
cancer research (2852) 2852
growth (2846) 2846
multidisciplinary sciences (2843) 2843
cell proliferation - drug effects (2810) 2810
protein kinase inhibitors - therapeutic use (2810) 2810
nsclc (2759) 2759
epidermal growth factor (2757) 2757
angiogenesis (2754) 2754
combined modality therapy (2743) 2743
antineoplastic combined chemotherapy protocols - adverse effects (2720) 2720
neoplasms. tumors. oncology. including cancer and carcinogens (2621) 2621
cell growth (2608) 2608
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (6) 6
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (6) 6
Online Resources - Online (5) 5
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Sunnybrook Health Sciences Centre - Online (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (51538) 51538
Chinese (653) 653
Japanese (609) 609
French (457) 457
German (231) 231
Italian (56) 56
Spanish (50) 50
Polish (48) 48
Portuguese (46) 46
Russian (36) 36
Hungarian (28) 28
Czech (22) 22
Dutch (20) 20
Danish (10) 10
Korean (8) 8
Romanian (7) 7
Serbian (7) 7
Norwegian (6) 6
Finnish (5) 5
Croatian (3) 3
Swedish (3) 3
Turkish (3) 3
Hebrew (2) 2
Lithuanian (2) 2
Arabic (1) 1
Bosnian (1) 1
Bulgarian (1) 1
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 9, pp. 829 - 838
...–small-cell lung cancer. Importantly, it reduced the risk of CNS relapse. 
RESISTANT | MEDICINE, GENERAL & INTERNAL | MODELS | ANTITUMOR-ACTIVITY | INHIBITOR ALECTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 371, Issue 21, pp. 1963 - 1971
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 378, Issue 2, pp. 113 - 125
In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had similar response rates, but osimertinib... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | CNS RESPONSE | AZD9291 | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Gefitinib | Lung Neoplasms - genetics | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Survival Rate | Piperazines - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Cancer patients | Care and treatment | Lung cancer, Non-small cell | Analysis | Tyrosine | Medical research | Epidermal growth factor receptors | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Oncology | Metastasis | Gene deletion | Patients | Cancer therapies | Clinical outcomes | Chemotherapy | Epidermal growth factor | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 372, Issue 18, pp. 1700 - 1709
Patients with non–small-cell lung cancer and mutated epidermal growth factor receptors who develop resistance to EGFR inhibitors through a particular mutation (T790M... 
TYROSINE KINASE INHIBITORS | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | GEFITINIB | ADENOCARCINOMA | ACQUIRED-RESISTANCE | MUTATIONS | AFATINIB | ERLOTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Humans | Middle Aged | ErbB Receptors - genetics | Lung Neoplasms - pathology | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Acrylamides - pharmacokinetics | Dose-Response Relationship, Drug | Hyperglycemia - chemically induced | Antineoplastic Agents - adverse effects | Female | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | ErbB Receptors - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Acrylamides - administration & dosage | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Acrylamides - adverse effects | Clinical trials | Care and treatment | Usage | Diagnosis | Lung cancer, Non-small cell | Hyperglycemia | Chemotherapy | Epidermal growth factor | Inhibitor drugs | Epidermal growth factor receptors | Lung cancer | Genes | Non-small cell lung carcinoma | Antitumor activity | Pharmacokinetics | Patients | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 370, Issue 13, pp. 1189 - 1197
...–small-cell lung cancer (NSCLC), ALK rearrangement occurs in approximately 5% of cases. 2 – 8 ALK -rearranged tumors depend on ALK for growth and survival and show marked sensitivity to ALK inhibitors such as crizotinib... 
TRIALS | MEDICINE, GENERAL & INTERNAL | GEFITINIB | EML4-ALK FUSION GENE | MUTATION | ACQUIRED-RESISTANCE | CRIZOTINIB | CLINICAL RESISTANCE | KINASE INHIBITOR | STI-571 | EGFR | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Sulfones - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Recombination, Genetic | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Treatment Outcome | Sulfones - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Maximum Tolerated Dose | Receptor Protein-Tyrosine Kinases - genetics | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Sulfones - administration & dosage | Antimitotic agents | Care and treatment | Dosage and administration | Research | Lung cancer, Non-small cell | Antineoplastic agents | Lung cancer | Diarrhea | Non-small cell lung carcinoma | Insulin-like growth factors | Dehydration | Kinases | Patients | Lymphoma | Gene amplification | Vomiting | Gene rearrangement | Hypophosphatemia | Antitumor activity | Mutation | Pharmaceutical industry | Protein-tyrosine kinase | Tumors
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 378, Issue 22, pp. 2078 - 2092
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 372, Issue 18, pp. 1689 - 1699
...–small-cell lung cancer in whom T790M-mediated drug resistance to other EGFR tyrosine kinase inhibitors had developed... 
MEDICINE, GENERAL & INTERNAL | GEFITINIB | PLACEBO | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | MUTATIONS | AFATINIB | IRREVERSIBLE EGFR | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Acrylamides - pharmacokinetics | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Aniline Compounds - administration & dosage | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | ErbB Receptors - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - genetics | Aniline Compounds - pharmacokinetics | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Acrylamides - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Aniline Compounds - adverse effects | Acrylamides - adverse effects | Clinical trials | Care and treatment | Usage | Diagnosis | Lung cancer, Non-small cell | Patient outcomes | Tyrosine | Appetite | Inhibitor drugs | Epidermal growth factor receptors | Lung cancer | Diarrhea | Nausea | Drug resistance | Kinases | Patients | Epidermal growth factor | Pharmacokinetics | Protein-tyrosine kinase | Index Medicus | Abridged Index Medicus
Journal Article